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Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that occurs predominantly in women of reproductive age [1]. Pregnancy induces dramatic immune 
and neuroendocrine changes in the maternal body to protect the 
fetus from immunologic attack and these modifications can be 
affected by SLE. Previous studies have shown that an association 
of SLE and pregnancy, mainly with active disease and especially 
with nephritis, has poorer pregnancy outcomes. There are 
increased chances of preeclampsia, fetal loss, prematurity, fetal 
growth restriction, small for gestational age babies, and neonatal 
lupus.
Pregnancy, on the other hand, may increase disease activity and 
results in lupus flare or active nephritis, which has the potential 
for accelerated end-stage renal disease. Therefore, SLE during 
pregnancy is considered a high-risk condition from both maternal 
and fetal aspect [2,3]. For a favorable pregnancy outcome, prenatal 
care of pregnant patients with SLE requires close collaboration 
between rheumatologist, obstetrician, pediatrician, sonologist, 
and biochemist in a tertiary care centre [4-6]. This case series 
aims to document the maternal and fetal outcomes in pregnant 
women with SLE.
CASE REPORT
All known cases of SLE, attending the antenatal clinic or admitted 
to the antenatal ward over a period of 1 year from 2012 to 2013 
in the Department of Obstetrics and Gynecology in a Medical 
College, Kolkata, were studied. All the cases were followed up for 
maternal and fetal outcomes. There were eight patients, six were 
booked (cases 1-6) and had a planned pregnancy, i.e. conceived 
after disease remission. Two cases were unbooked (cases 7 and 
8) and had an unplanned pregnancy, conceived during active 
disease. All 8 patients had lupus nephritis (LN), diagnosed using 
American College of Rheumatology criteria (1997 Update of the 
1982 American College of Rheumatology Revised Criteria) for 
classification of SLE.
Histological grading of renal involvement of the patients 
was done according to the World Health Organization 
classification [7]/2004 classification of International Society 
of Nephrology/Renal Pathology Society as follows: Class I 
- minimal mesangial LN; Class II - mesangial proliferative LN; 
Class III - focal LN; Class IV - diffuse LN; Class V - membranous 
LN; and Class VI - advanced sclerosing LN.
At the first visit, the previous medical, obstetric, and treatment 
history were recorded and clinical examination and necessary 
serological evaluations (namely antinuclear antibody [ANA], 
anti-ds DNA antibodies [IgM and IgG], anti-cardiolipin antibodies 
[IgM and IgG], anti-β2 glycoprotein-I [IgM and IgG], anti-SSA 
Ab, anti-SSB Ab, and C3 and C4) were carried out. SLE activity 
in each patient was assessed using SLE disease activity index-2K 
before pregnancy/at first visit and at the end of each trimester to 
monitor the SLE activity.
Active nephritis was considered if the patients had any 
one of the following at admission: >0.5 g proteinuria in a 24-h 
urine sample or red blood cell casts in urine. Cases 1-6 were 
followed up regularly in the gynecology and obstetrics OPD and 
the medicine OPD during the antenatal period and admitted at 
32 weeks of conception for safe confinement. Cases 7 and 8 were 
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admitted through the emergency. After admission, all 8 patients 
were followed closely till delivery and post-delivery disease 
monitoring was continued up to 12 months. As this was a case 
series and no intervention was done, ethical committee clearance 
and patient consent were not needed.
The baseline features and clinical characteristics of all 
patients are summarized in Table 1. Cases 2, 3, 5, and 6 were 
primigravida while cases 1 and 4 had previous three and four 
spontaneous abortions, respectively, before being diagnosed with 
SLE. Case 6 had a history of myocarditis and neuropsychiatric 
manifestations leading to her diagnosis of SLE but showed no 
such symptoms after conception. Cases 1–6 did not show any sign 
of disease activity after conception as evident from negative test 
results (anti-ds DNA, anti-Ro/La, ANA, serum urea, and serum 
creatinine). Preeclampsia developed only in case 4. In other 
cases, the blood pressure was normal throughout pregnancy as 
shown in Table 2.
The pregnancy outcomes have been tabulated in Table 3. All 
6 patients delivered live-born babies by lower segment cesarean 
section (LSCS), two of them being low birth weight due to preterm 
prelabor rupture of membranes, necessitating emergency LSCS. 
No sign of neonatal lupus in the form of cutaneous manifestations 
or congenital heart block was seen in any of the babies at birth 
and also at 6 weeks follow-up.
Cases 7 and 8 were unbooked cases and were admitted 
through emergency at 34 and 28 weeks of gestation, 
respectively. The patients had signs of active SLE such as a 
malar rash (Fig. 1), oral ulcers, proteinuria and microscopic 
hematuria and raised serum urea, and creatinine levels at 
presentation. Case 7 presented with less fetal movement, no 
signs of pregnancy-induced hypertension (PIH) was seen. 
Ultrasonography for fetal viability showed intrauterine fetal 
death. Case 8 developed PIH along with SLE flare at 36 weeks 
requiring an emergency cesarean section. There was no 
evidence of deep vein thrombosis in any of the cases. The 
microscopic image of glomerulonephritis and skin changes is 
shown in Figs. 2 and 3.
DISCUSSION
In this case series, we found that pregnancy outcome was the 
best when patients conceived during remission phase and had 
proper antenatal care. Fertility rates are normal in women with 
Table 1: Demography of the patients (n=8)
Case Age 
(years)
Married 
for  
(in years)
Gravida 
and 
parity
Lab data 
pre-conception
WHO class 
of SLE 
nephritis
Duration since 
diagnosis  
(years)
T/t (pre-conception)
1 (B)* 19 2 G1 P0+3 II (MPGN) 2 Steroid(↑dose) +ACE-I
2 (B) 21 2 G1 P0+0 II (MPGN) 2 -do-
3 (B) 22 2 G1 P0+0 ANA+ IV (DPGN) 5 -do-+Azathioprine
4 (B) 31 8 G5 P0+4 APLA+ANA+ V (MGN) 3 Steroid(↑dose)+ACE-I
5 (B) 24 3 G1 P0+0 II (MPGN) 2 -do-
6 (B) 26 6 G1 P0+0 III (focal GN) 5 Steroid (↑dose)+Cyclophosphamide
7 (UB)# 27 9 G7 P1+5
(LI-nil)
Kidney biopsy 
not available
1 Steroid (↑dose)+HCQS (discontinued)
8 (UB) 23 8 G3 P1+1
(LI-1)
Kidney biopsy 
not available
2 Steroid (↑dose)+HCQS
*B: Booked, #UB: Unbooked, MPGN: Membranoproliferative glomerulonephritis, DPGN: Diffuse proliferative glomerulonephritis, MGN: membranous glomerulonephritis, 
ANA: Antinuclear antibody, SLE: Systemic lupus erythematosus, WHO: World Health Organization
Figure 1: Butterfly rashes seen in the face of the patient with systemic 
lupus erythematosus
Figure 2: Microscopic image of glomerulonephritis
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SLE. However, pregnancy in the background of SLE is prone 
to complications and hence, must be considered at high risk 
[8]. Prognosis for both mother and child is best when SLE is 
quiescent for at least 6 months before the pregnancy [9,10], and 
the mother’s renal function is stable. LN can get worse during 
pregnancy. In a previous case series of 86 cases, the maternal 
outcome is worst in active nephritis [11]. Pregnancy loss is more 
likely if SLE is diagnosed during the index pregnancy or if patient 
conceives before the disease is in remission.
In our study, 6/8 of the cases were planned pregnancies conceived 
after at least 6 months of disease quiescence. They had good maternal 
and fetal outcome with proper medication and careful monitoring. 
No evidence of SLE flare or any other maternal complications were 
seen, except for the development of preeclampsia in one patient. 
Following delivery, treatment was continued as per pre-pregnancy 
schedule. Patients were followed up after 6 weeks and at 3 monthly 
intervals for a year thereafter. No evidence of neonatal lupus or 
maternal disease flare was seen in any of the cases.
Case 7 was an unplanned pregnancy with poor patient 
compliance resulting in flare-up of SLE and pregnancy loss. 
Following delivery, treatment was continued as per pre-pregnancy 
schedule and patient was advised not to conceive until after 
6 months of disease remission. Case 8 was also an unplanned 
pregnancy, conceived during active disease. But compliance to 
medications and vigilant maternal and fetal monitoring led to 
early diagnosis and management of complications (like PIH) and 
a successful pregnancy outcome. Following delivery, treatment 
was continued as per pre-pregnancy schedule. She was discharged 
after control of disease flare and followed up for a year. The 
postpartum period was uneventful.
Table 2: Treatment received
Case Admission BP s/s Urine RE/ME Lab data (on 
admission)
T/t (post-conception)
Via POG 
(week)
Proteinuria RBC/Casts
1 (B) OPD 32 N Trace Nil WNL Steroid (↓dose),
Aspirin (↓dose)
2 (B) OPD 32 N Trace Nil WNL -do-
3 (B) OPD 32 N Trace Nil WNL -do-
+ Azathioprine
4 (B) OPD 32 N initially↑after 
36w
H/O DVT 1+ Nil ↑ESR
APLA-positive
Steroid (↓dose),
Aspirin (↓dose),
LMWH
5 (B) OPD 35 N 1+ Nil WNL Steroid (↓dose),
Aspirin (↓dose)
6 (B) OPD 32 N Trace Nil WNL Steroid (↓dose),
Aspirin (↓dose)
7 (UB) ER 34 N Malar rash, 
Oral ulcer, 
less fetal 
movement
1+ RBC+>5/hpf ↑anti-dsDNA↑anti-Ro/
La antibody
C3-WNL
APLA-negative↑Se 
urea,
Creatinine
-do-
8 (UB) ER 28 N initially; 
↑after 34 week
Malar rash, 
oral ulcer, 
psychosis
1+ RBC+>5/hpf ↑dsDNA, ↑ESR
CRP, C3-WNL↑Se 
urea, creatinine
-do-
B: Booked, UB: Unbooked, RBC: Red blood cell, ESR: Erythrocyte sedimentation rate, CPR: C-reactive protein
Table 3: Outcome of treatment
Case Pregnancy 
complications
POG at 
delivery (weeks)
Mode of delivery Live/still born Birth 
weight (kg)
Apgar 
score (1 min)
Neonatal 
complication
1 (B) None  
(H/O- BOH)
38 LSCS’ Live 2.9 9 None
2 (B) None 38 LSCS Live 2.6 9 None
3 (B) PPROM 35 LSCS Live 2.2 6 RDS
4 (B) PET, PPROM 36 LSCS Live 2.25 6 RDS
5 (B) None 37 LSCS Live 2.4 9 None
6 (B) None 38 LSCS Live 2.7 9 None
7 (UB) IUFD 34 VD Stillborn 
(macerated)
1.25 _ _
8 (UB) Preecalmpsia 37 LSCS Live 2.0 5 RDS, Sepsis
B: Booked, UB: Unbooked, LSCS: Lower segment cesarean section, IUFD: Intrauterine fetal death, RDS: Respiratory distress syndrome, PPROM: Premature rupture of membranes
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In our study, the use of azathioprine (as seen being used in 
case 3) was not associated with teratogenicity in a patient with 
SLE in pregnancy. Some studies have suggested that exposure to 
azathioprine during pregnancy is not associated with poor fetal 
outcome [10-12]. The main limitation of this study is that the 
number of cases is very small. We are presently continuing the 
study and hope to come up with more number of cases in the 
future.
CONCLUSION
A planned pregnancy after disease remission is an essential pre-
requisite for successful pregnancy outcome in SLE patients. 
Regular antenatal care and fetal monitoring are essential, 
especially in anti-Ro, anti-La positive patients. Early diagnosis 
of complications and their prompt management and optimal 
timing of delivery are essential for good maternal and fetal 
outcome.
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Figure 3: Microscopic picture of skin changes
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